These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 34450231)

  • 1. Lessons from S1P receptor targeting in multiple sclerosis.
    Colombo E; Farina C
    Pharmacol Ther; 2022 Feb; 230():107971. PubMed ID: 34450231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingosine-1-phosphate receptor modulators in stroke treatment.
    Zhang W; Li Y; Li F; Ling L
    J Neurochem; 2022 Sep; 162(5):390-403. PubMed ID: 35943290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
    Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.
    Tsai HC; Han MH
    Drugs; 2016 Jul; 76(11):1067-79. PubMed ID: 27318702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
    Hla T; Brinkmann V
    Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement.
    Bordet R; Camu W; De Seze J; Laplaud DA; Ouallet JC; Thouvenot E
    Rev Neurol (Paris); 2020; 176(1-2):100-112. PubMed ID: 31757428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
    Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation.
    Blaho VA; Galvani S; Engelbrecht E; Liu C; Swendeman SL; Kono M; Proia RL; Steinman L; Han MH; Hla T
    Nature; 2015 Jul; 523(7560):342-6. PubMed ID: 26053123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A; Kihara Y; Chun J
    J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
    Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
    Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.
    Chun J; Kihara Y; Jonnalagadda D; Blaho VA
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():149-170. PubMed ID: 30625282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles for lysophospholipid S1P receptors in multiple sclerosis.
    Noguchi K; Chun J
    Crit Rev Biochem Mol Biol; 2011 Feb; 46(1):2-10. PubMed ID: 20979571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and Optimization of
    Gusman DH; Shoemake C
    Yale J Biol Med; 2017 Mar; 90(1):15-23. PubMed ID: 28356890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J; Hartung HP
    Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
    Spampinato SF; Obermeier B; Cotleur A; Love A; Takeshita Y; Sano Y; Kanda T; Ransohoff RM
    PLoS One; 2015; 10(7):e0133392. PubMed ID: 26197437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    McGinley MP; Cohen JA
    Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting sphingosine 1-phosphate (S1P) levels and S1P receptor functions for therapeutic immune interventions.
    Gräler MH
    Cell Physiol Biochem; 2010; 26(1):79-86. PubMed ID: 20502007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P
    Stepanovska Tanturovska B; Zivkovic A; Imeri F; Homann T; Kleuser B; Stark H; Huwiler A
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.